Let Every Single Cell Tell Its Story
Heterogeneity is defined as the quality or state of being diverse in character or content. Cellular heterogeneity drives our diversity as humans via a set of variations in our DNA, resulting in the differences we see in our attributes, senses and ability to live a long, healthy life. These DNA changes can also drive the development of diseases, such as cancer, and better understanding the cell to cell genomic variability is critical for the development of more precise and effective treatments.
The BioSkryb Advantage
The cell is the building block of life. It drives the function of physiological processes and is ultimately responsible for human health. Better understanding those processes and how defects in them lead to human disease requires analyzing down to the single cell level. Unfortunately, most research is not executed to single cell resolution or looks at an incomplete picture of the molecular determinates of disease. To meet that need, BioSkryb Genomics is ushering in a new era of single-cell analysis. With our patented Primary Template-directed Amplification (PTA), BaseJumper™ bioinformatics platform, and other technologies and services, we support scientific discoveries revealing multiple tiers of dynamic molecular information all from a single cell. Those discoveries drive novel biological insights and deliver a more complete understanding of the relationship between genes and disease, advancing the development of more precise treatments. Let us show you what you have been missing.
ResolveOME uses a unified workflow to amplify the genome and transcriptome from the same cell simultaneously, eliminating the need to split samples and the need to cross reference data. Experience a new era of mutiomic analysis.
BaseJumper is an easy-to-use bioinformatics platform with the ability to visualize data in an intuitive layout to drive the discovery of complex molecular characteristics of single-cell genomics.
"PTA is our method of choice if you want reproducible, efficient, and evenly amplified genomes from single cells for single nucleotide variant detection."
Bullard Professor of Neurology, Harvard Medical School Chief Division of Genetics, Boston Children’s Hospital Investigator, Howard Hughes Medical Institute
"The BioSkryb team was a great partner in assisting us with single-cell sequencing and analysis. They were responsive to our unique needs and the results and insights their technology provided far exceeded our expectations. BioSkryb’s commitment to supporting us in our fight against cancer using cell and gene therapies was present every step of the way. We highly recommend them for their products, services, and a customer-centric approach.”
CEO, Falcon Therapeutics
"I have tried several whole-genome amplification methods, and none compare to the high reliability and high fidelity of PTA.”
Michael Lodato, Ph.D.
Assistant Professor, Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School